Stock listing
NASDAQ:ERAS Erasca, Inc. Stock
Home listing (NASDAQ) of Erasca, Inc.
Follow Erasca, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ERAS
$13.61 USD -0.15 (-1.1%)
Close on Nov 20, 2026
- Day range
- $13.13 – $14.31 USDNov 20, 2026
- Volume
- 11.07M sharesNov 20, 2026
- Market cap
- $4.78B USDAt the close on Nov 20, 2026 · price × 351.0M shares outstanding
- 52-week range
- $2.75 – $24.28 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $79.44M USDMedian day 4.42M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ERAS · Home | $13.61 USD | -0.15 (-1.1%) | 11,072,619 | $13.13 | $14.31 | $13.13 | $13.76 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ERAS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $13.61 | -0.15 | -1.1% | $13.13 | $14.31 | $13.13 | 11,072,619 | |
| $13.76 | -0.13 | -0.9% | $13.97 | $14.14 | $13.03 | 8,941,061 | |
| $13.89 | -1.22 | -8.1% | $15.51 | $15.69 | $13.60 | 8,789,965 | |
| $15.11 | -0.55 | -3.5% | $15.49 | $15.84 | $14.87 | 5,827,312 | |
| $15.66 | -0.12 | -0.8% | $15.29 | $15.83 | $14.17 | 8,533,403 | |
| $15.78 | -1.02 | -6.1% | $16.22 | $16.22 | $15.16 | 4,897,335 | |
| $16.80 | +1.32 | +8.5% | $15.78 | $17.34 | $15.58 | 13,794,006 | |
| $15.48 | -0.13 | -0.8% | $15.43 | $15.66 | $15.00 | 5,984,545 | |
| $15.61 | +1.20 | +8.3% | $14.57 | $15.69 | $14.13 | 4,701,552 | |
| $14.41 | +1.14 | +8.6% | $13.42 | $14.43 | $13.11 | 4,030,116 | |
| $13.27 | -1.64 | -11.0% | $14.91 | $15.18 | $13.17 | 6,687,563 | |
| $14.91 | +0.27 | +1.8% | $15.09 | $15.09 | $14.18 | 3,494,665 | |
| $14.64 | +0.59 | +4.2% | $14.30 | $15.00 | $14.07 | 3,798,381 | |
| $14.05 | -0.30 | -2.1% | $14.76 | $15.38 | $13.72 | 4,388,524 | |
| $14.35 | -0.63 | -4.2% | $14.66 | $15.01 | $14.04 | 3,749,182 | |
| $14.98 | -0.14 | -0.9% | $15.11 | $15.45 | $14.66 | 2,280,740 | |
| $15.12 | -0.10 | -0.7% | $15.20 | $15.32 | $14.45 | 3,391,417 | |
| $15.22 | +0.23 | +1.5% | $14.95 | $15.26 | $14.72 | 5,825,490 | |
| $14.99 | +0.60 | +4.2% | $14.58 | $15.47 | $14.55 | 6,466,115 | |
| $14.39 | +0.35 | +2.5% | $13.99 | $14.45 | $13.44 | 3,498,640 | |
| $14.04 | -0.45 | -3.1% | $14.22 | $14.65 | $13.82 | 2,296,073 | |
| $14.49 | -0.13 | -0.9% | $14.82 | $15.05 | $14.38 | 3,845,038 | |
| $14.62 | +1.00 | +7.3% | $13.40 | $14.97 | $13.10 | 4,218,224 | |
| $13.62 | +0.23 | +1.7% | $13.73 | $13.98 | $13.34 | 4,263,888 | |
| $13.39 | -1.48 | -10.0% | $14.87 | $14.87 | $13.27 | 7,089,200 | |
| $14.87 | +0.17 | +1.2% | $14.71 | $15.26 | $14.36 | 8,481,000 | |
| $14.70 | -0.08 | -0.5% | $14.41 | $15.08 | $14.29 | 4,747,500 | |
| $14.78 | -0.68 | -4.4% | $15.25 | $15.58 | $14.50 | 5,313,600 | |
| $15.46 | -0.57 | -3.6% | $15.89 | $16.01 | $15.32 | 4,280,300 | |
| $16.03 | +0.57 | +3.7% | $15.42 | $16.20 | $15.22 | 7,772,000 | |
| $15.46 | +1.34 | +9.5% | $13.96 | $15.62 | $13.78 | 9,611,600 | |
| $14.12 | -0.18 | -1.3% | $14.09 | $14.57 | $13.93 | 3,853,900 | |
| $14.30 | -0.42 | -2.9% | $14.74 | $14.93 | $14.02 | 8,042,600 | |
| $14.72 | -0.02 | -0.1% | $14.74 | $15.03 | $13.80 | 5,486,200 | |
| $14.74 | +0.16 | +1.1% | $14.81 | $15.27 | $14.57 | 3,836,900 | |
| $14.58 | -0.08 | -0.5% | $14.66 | $15.01 | $14.33 | 3,691,700 | |
| $14.66 | +0.45 | +3.2% | $14.37 | $15.12 | $14.11 | 5,286,400 | |
| $14.21 | +0.08 | +0.6% | $14.10 | $14.43 | $13.82 | 3,203,300 | |
| $14.13 | -0.12 | -0.8% | $14.53 | $14.62 | $13.86 | 3,597,300 | |
| $14.25 | -0.27 | -1.9% | $14.62 | $14.89 | $14.23 | 3,218,200 | |
| $14.52 | +0.575 | +4.1% | $13.82 | $15.07 | $13.54 | 6,266,600 | |
| $13.95 | -1.605 | -10.3% | $15.55 | $15.55 | $13.94 | 4,423,900 | |
| $15.55 | +0.51 | +3.4% | $15.17 | $15.78 | $15.09 | 4,765,400 | |
| $15.04 | +0.27 | +1.8% | $14.96 | $15.29 | $14.60 | 4,151,200 | |
| $14.77 | -0.57 | -3.7% | $15.41 | $15.47 | $14.51 | 8,687,400 | |
| $15.34 | -0.02 | -0.1% | $15.83 | $16.32 | $14.92 | 7,548,600 | |
| $15.36 | -0.89 | -5.5% | $16.31 | $16.64 | $15.19 | 6,086,100 | |
| $16.25 | +0.09 | +0.6% | $16.14 | $16.29 | $15.54 | 4,689,700 | |
| $16.16 | +0.28 | +1.8% | $16.06 | $16.53 | $15.97 | 2,363,500 | |
| $15.88 | -0.15 | -0.9% | $16.05 | $16.54 | $15.87 | 2,883,800 | |
| $16.03 | +0.33 | +2.1% | $15.37 | $17.25 | $15.37 | 8,248,100 | |
| $15.70 | -0.58 | -3.6% | $16.06 | $16.70 | $15.67 | 4,041,900 | |
| $16.28 | +0.09 | +0.6% | $15.88 | $16.65 | $15.68 | 4,264,700 | |
| $16.19 | -0.07 | -0.4% | $16.04 | $16.40 | $15.77 | 2,055,100 | |
| $16.26 | -0.11 | -0.7% | $16.38 | $16.57 | $16.09 | 3,761,800 | |
| $16.37 | -0.39 | -2.3% | $16.97 | $17.45 | $15.78 | 5,121,100 | |
| $16.76 | -1.12 | -6.3% | $17.58 | $17.95 | $16.68 | 6,708,100 | |
| $17.88 | -0.15 | -0.8% | $17.87 | $18.03 | $17.14 | 4,766,100 | |
| $18.03 | -1.46 | -7.5% | $19.25 | $19.59 | $18.00 | 2,887,300 | |
| $19.49 | +0.34 | +1.8% | $19.30 | $20.40 | $19.14 | 4,122,500 | |
| $19.15 | +1.39 | +7.8% | $17.57 | $19.50 | $17.24 | 7,690,600 | |
| $17.76 | +0.16 | +0.9% | $17.80 | $18.50 | $17.70 | 2,663,100 | |
| $17.60 | -0.03 | -0.2% | $18.41 | $18.66 | $16.88 | 2,244,400 | |
| $17.63 | +0.55 | +3.2% | $17.28 | $17.84 | $17.21 | 2,445,400 | |
| $17.08 | -0.99 | -5.5% | $17.59 | $17.77 | $16.92 | 2,666,400 |
- Ticker
- NASDAQ:ERAS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
Latest deck · November 2026
EORTC-NCI-AACR (ENA) Symposium 2026
Conference · 16 slides
Latest news
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
Nov 20, 2026
Closed $13.61 (-1.1%) on Nov 20, 2026
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
Nov 17, 2026
Closed $13.76 (-0.9%) on Nov 18, 2026
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
Nov 16, 2026
Closed $15.11 (-3.5%) on Nov 16, 2026
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
Nov 12, 2026
Closed $15.66 (-0.8%) on Nov 13, 2026
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Nov 4, 2026
Closed $14.91 (+1.8%) on Nov 4, 2026
Erasca to Present at Upcoming Conferences in November
Nov 3, 2026
Closed $14.64 (+4.2%) on Nov 3, 2026
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Sep 10, 2026
Closed $16.03 (+2.1%) on Sep 10, 2026
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Sep 8, 2026
Closed $16.28 (+0.6%) on Sep 8, 2026
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Aug 24, 2026
Closed $17.60 (-0.2%) on Aug 24, 2026
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
Aug 11, 2026
Closed $18.58 (+1.5%) on Aug 12, 2026
Erasca, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 125 in all · newest Nov 20, 2026 · oldest 2021
- Decks
- 12 decks · latest November 2026
Where Erasca, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ERAS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ERAS | BOATS | United States | USD |
Valuation
Price/book 5.2× against a median of 6.6×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $4.18B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 5.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.51
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Erasca, Inc. · NASDAQ:ERAS | US$4.78B | US$4.18B | n/a | n/a | n/a | 5.2× | n/a | 0.1× | 1.51 |
| Belite Bio, Inc. · NASDAQ:BLTE | US$5.13B | US$5.13B | n/a | n/a | n/a | 6.6× | n/a | 0.0× | 1.34 |
| SK Biopharmaceuticals Co., Ltd. · KRX:326030 | US$5.08B | US$4.80B | 16.9× | 7.5× | 20.1× | 6.7× | 46.6% | 0.0× | n/a |
| Veradermics, Incorporated · NYSE:MANE | US$5.04B | US$4.25B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.13 |
| Liquidia Corporation · NASDAQ:LQDA | US$4.90B | US$4.68B | n/a | 7.5× | n/a | n/a | −15.2% | n/a | 0.84 |
| Dianthus Therapeutics, Inc. · NASDAQ:DNTH | US$4.76B | US$3.92B | n/a | 1,444× | n/a | 3.8× | n/a | 0.0× | 0.90 |
| PTC Therapeutics, Inc. · NASDAQ:PTCT | US$4.71B | US$3.12B | n/a | 2.7× | n/a | n/a | −9.2% | n/a | 0.88 |
| Cogent Biosciences, Inc. · NASDAQ:COGT | US$4.65B | US$4.08B | n/a | n/a | n/a | 9.0× | n/a | 0.4× | 1.30 |
| Kiniksa Pharmaceuticals International, plc · NASDAQ:KNSA | US$4.53B | US$3.97B | 41.4× | 4.2× | 29.9× | 6.4× | 11.6% | 0.0× | 0.57 |
| Travere Therapeutics, Inc. · NASDAQ:TVTX | US$4.51B | US$4.21B | n/a | 6.5× | n/a | 200× | −18.7% | 0.0× | 1.31 |
| Ionis Pharmaceuticals, Inc. · NASDAQ:IONS | US$4.43B | US$4.70B | n/a | 4.9× | n/a | 11.3× | −56.9% | 5.5× | 0.40 |
| Median of the others | US$4.74B | US$4.23B | 29.2× | 6.5× | 25.0× | 6.6× | −12.2% | 0.0× | 0.90 |
Forecasts
6 strong buy · 2 buy · 2 hold · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 25.10 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.02 · 9 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jonathan E. Lim | Chairman, CEO and Co-founder |
| David Chacko | Chief Financial Officer and Chief Business Officer |
| Charles S. Fuchs | President, Research and Development |
| Nik Chetwyn | Chief Operating Officer |
| Ebun Garner | Chief Legal Officer |
| Chandra Lovejoy | Chief Regulatory Affairs Officer |
| Lisa Tesvich-Bonora | Chief People Officer |
| Robert Shoemaker | Chief Scientific Officer |
| Shannon Morris | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Jonathan E. Lim | Chairman, CEO and Co-founder |
| Michael Varney | Chair of R&D, SAB Member and Board Director |
| Alexander W. Casdin | Board Director |
| James A. Bristol | Board Director |
| Jean I. Liu | Board Director |
| Julie Hambleton | Board Director |
| Val Harding | Board Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −0.8% |
| Q2 2026 | Aug 11, 2026 · After close | +1.5% |
| Q1 2026 | May 11, 2026 · After close | −0.6% |
| Q4 2025 | Mar 19, 2026 | +8.2% |
| Q3 2025 | Nov 12, 2025 · After close | −4.2% |
| Q2 2025 | Aug 12, 2025 · After close | +3.9% |
| Q1 2025 | May 13, 2025 · After close | −4.5% |
| Q4 2024 | Mar 20, 2025 | +3.4% |
| Q3 2024 | Nov 12, 2024 · After close | −4.7% |
| Q2 2024 | Aug 12, 2024 · After close | +0.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −8.8% |
| Q4 2023 | Mar 27, 2024 · After close | 0.0% |
| Q3 2023 | Nov 9, 2023 · After close | 0.0% |
| Q2 2023 | Aug 10, 2023 · After close | +11.9% |
| Q1 2023 | May 15, 2023 · After close | −4.0% |
| Q4 2022 | Mar 23, 2023 · After close | +1.8% |
| Q3 2022 | Nov 9, 2022 · After close | +16.6% |
| Q2 2022 | Aug 11, 2022 · After close | +15.3% |
| Q1 2022 | May 12, 2022 · After close | −0.2% |
| Q4 2021 | Mar 24, 2022 · After close | +7.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| EORTC-NCI-AACR (ENA) Symposium 2026 | Conference | 16 slides | November 2026 |
| Investor Presentation (August 2026) | Investor deck | 49 slides | August 2026 |
| Investor Presentation (January 2026) | Investor deck | 31 slides | Jan 12, 2026 |
| Investor Presentation (January 2025) | Investor deck | 51 slides | Jan 13, 2025 |
| Investor Presentation (May 2024) | Investor deck | 49 slides | May 16, 2024 |
| ASCO 2024 | Conference | 11 slides | May 2024 |
| Investor Presentation (January 2024) | Investor deck | 41 slides | Jan 9, 2024 |
| Investor Presentation (June 2023) | Investor deck | 35 slides | Jun 5, 2023 |
| Investor Presentation (January 2023) | Investor deck | 63 slides | Jan 9, 2023 |
| Investor Presentation (December 2022) | Investor deck | 81 slides | Dec 9, 2022 |
All 12 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (September 2022) | Investor day | 62 slides | Sep 7, 2022 |
| Technical Presentation (October 2021) | Technical | 28 slides | Oct 25, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares Closed: US$632.5M raised · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead) Use of proceeds: Fund ERAS-0015 toward three potentially registration-enabling trials and the broader pipeline milestones | Aug 11, 2026 |
| Public offering of common stock Closed: US$258.8M raised · US$10 a share · J.P. Morgan +3 Dealers: J.P. Morgan (co-lead), Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead) Use of proceeds: Research and development of product candidates and other programs, working capital and general corporate purposes | Jan 23, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jul 15, 2021.
- Price
- US$16.00 a share
- Shares offered
- 18,750,000 shares of common stock
- Offering size
- US$300 million
- Underwriters' option
- Up to 2,812,500 more shares
- Underwriters
- J.P. Morgan, Morgan Stanley, BofA Securities, Evercore ISI, Guggenheim Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 7, 2021 |
| Filed publicly | Jun 25, 2021 |
| Amended once | Jul 12, 2021 |
| Shares registered with an exchange | Jul 13, 2021 |
| Declared effective by the SEC | Jul 15, 2021 |
| Final prospectus, with the price | Jul 16, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 16, 2021 |
| EFFECT · Notice that a registration is effective | Jul 15, 2021 |
| S-1MEF · Registration of more shares for the same offering | Jul 15, 2021 |
| CERT · Exchange's certificate of listing | Jul 15, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 13, 2021 |
| CORRESP · Letter to the SEC | Jul 12, 2021 |
| S-1/A · Registration statement, amended | Jul 12, 2021 |
| UPLOAD · Letter from the SEC | Jul 9, 2021 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jun 28, 2021 |
| CORRESP · Letter to the SEC | Jun 25, 2021 |
| S-1 · Registration statement | Jun 25, 2021 |
| UPLOAD · Letter from the SEC | Jun 21, 2021 |
| DRSLTR · Letter to the SEC with a draft | Jun 9, 2021 |
| DRS/A · Draft registration statement, amended | Jun 9, 2021 |
| UPLOAD · Letter from the SEC | Jun 2, 2021 |
| DRS · Draft registration statement | May 7, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 16, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 3.11M | 3.81M | 3.73M | 2.64M | 829.0K | 540.0K | 310.0K |
| Gross profit | -3.11M | -3.81M | -3.73M | -2.64M | -829.0K | -540.0K | -310.0K |
| Research and development | 92.9M | 115.4M | 103.8M | 112.5M | 73.9M | 29.6M | 9.62M |
| Selling, general and administrative | 38.6M | 41.7M | 37.7M | 33.0M | 22.6M | 7.96M | 3.68M |
| Operating income | -140.9M | -179.6M | -141.5M | -247.4M | -124.9M | -109.3M | -13.3M |
| Depreciation and amortization | 3.11M | 3.81M | 3.73M | 2.64M | 829.0K | 540.0K | 310.0K |
| EBITDA | -137.8M | -175.8M | -137.8M | -244.8M | -124.1M | -108.7M | -13.0M |
| Interest expense | 201.4M | 55.9M | 336.0K | 0 | |||
| Income before tax | -124.5M | -161.7M | -125.0M | -242.8M | -122.8M | -101.7M | -12.0M |
| Income tax | 0 | 0 | -4.64M | 27.3M | 71.4M | -1.30M | |
| Net income | -124.5M | -161.7M | -125.0M | -242.8M | -122.8M | -101.7M | -12.0M |
| Earnings per share, basic | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 | -4.83 | -0.13 |
| Earnings per share, diluted | -0.44 | -0.69 | -0.83 | -1.99 | -1.85 | -4.83 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | 73.8M | 67.7M | 93.1M | 284.2M | 360.5M | 65.4M | 29.6M |
| Short-term investments | 202.3M | 230.6M | 219.3M | 151.4M | 54.0M | 53.3M | 20.8M |
| Receivables | 2.50M | 2.30M | 100.0K | ||||
| Current assets | 286.2M | 308.8M | 320.7M | 444.5M | 420.0M | 120.0M | 51.1M |
| Property, plant and equipment | 13.3M | 16.3M | 22.3M | 24.8M | 16.0M | 1.85M | 4.33M |
| Total assets | 396.2M | 502.5M | 395.3M | 514.9M | 501.4M | 124.8M | 55.5M |
| Accounts payable | 981.0K | 468.0K | 2.00M | 23.0M | 4.68M | 878.0K | 1.38M |
| Current liabilities | 28.5M | 31.4M | 26.2M | 48.7M | 26.2M | 13.7M | 2.75M |
| Total debt | 47.1M | 51.9M | 55.9M | 55.1M | 18.8M | 2.99M | 3.69M |
| Total liabilities | 71.0M | 79.0M | 78.6M | 103.1M | 44.9M | 17.4M | 69.1M |
| Shareholders' equity | 325.2M | 423.5M | 316.7M | 411.9M | 456.5M | -114.0M | -13.6M |
| Shares outstanding | 284.2M | 283.2M | 151.1M | 149.3M | 119.1M | 21.9M | 95.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -95.5M | -109.4M | -101.2M | -103.3M | -79.6M | -32.7M | -10.4M |
| Capital spending | -128.0K | -60.0K | -1.77M | -14.6M | -11.2M | -947.0K | -597.0K |
| Free cash flow | -95.6M | -109.5M | -103.0M | -117.8M | -90.8M | -33.6M | -11.0M |
| Cash from investing | 100.4M | -156.6M | -91.2M | -71.1M | -64.6M | -71.2M | -20.9M |
| Cash from financing | 1.10M | 240.7M | 1.29M | 98.1M | 439.4M | 140.0M | 16.9M |
| Share buybacks | 724.0K | 800.0K | 790.0K | 820.0K | 1.07M | ||
| Change in cash | 6.07M | -25.3M | -191.1M | -76.3M | 295.2M | 36.1M | -14.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 20, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Nov 16, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 16, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Oct 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 24, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 144 · Notice of proposed sale | Aug 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 12, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 8-K · Current report | Aug 10, 2026 | Management or board change | SEC |
| 144 · Notice of proposed sale | Jul 21, 2026 | Other filings | SEC |
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jul 14, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jul 13, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| S-3ASR · Registration statement | Jul 13, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 30, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 15, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| 8-K · Current report | Apr 21, 2026 | Current report | SEC |
| 144/A · Notice of proposed sale, amended | Apr 15, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 16, 2026 | Other filings | SEC |
| 10-K · Annual report | Mar 12, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2026 | Results | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 17, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 29, 2026 | Current report | SEC |
| 8-K · Current report | Jan 22, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 20, 2026 | Results | SEC |
| 424B5 · Prospectus | Jan 20, 2026 | Offer document | SEC |
| 144 · Notice of proposed sale | Jan 15, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 14, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Oct 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 18, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 13, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Jul 15, 2025 | Other filings | SEC |
| 8-K · Current report | Jun 26, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 16, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 15, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 15, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 20, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Mar 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 5, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 15, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Oct 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 24, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| 144 · Notice of proposed sale | Oct 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 16, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Jul 15, 2024 | Other filings | SEC |
| 8-K · Current report | Jun 24, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 17, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | May 31, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 29, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | May 28, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | May 17, 2024 | Offer document | SEC |
| 8-K · Current report | May 17, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 17, 2024 | Other filings | SEC |
| 8-K · Current report | May 16, 2024 | Material contract | SEC |
| 144 · Notice of proposed sale | May 15, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2024 | Other filings | SEC |
| S-3 · Registration statement | May 9, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 144 · Notice of proposed sale | Apr 15, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 28, 2024 | Material contract | SEC |
| 10-K · Annual report | Mar 27, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2024 | Results | SEC |
| 144 · Notice of proposed sale | Mar 15, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 15, 2024 | Other filings | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 7, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 30, 2024 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jan 16, 2024 | Other filings | SEC |
| 8-K · Current report | Jan 9, 2024 | Current report | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2024 | Insider trade | SEC |
This page holds 200 of 358 filings. Open Filings
Cap table
Built by 6ix from Erasca, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 350,956,416
- Fully diluted
- 350,956,416
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 350,956,416 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 350,956,416 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Lin Wei Other companies: TCGX Acquisition Corp. (Director · Since at least Aug 4, 2026); Revolution Medicines, Inc. (Chief Medical Officer · Since at least Mar 21, 2024); 2Seventy Bio Inc (Director · Mar 7, 2023 – May 13, 2025 · Past) | Chief Medical Officer · Jul 15, 2021 – Feb 1, 2023 · Past |
| James Bristol Other companies: Ernexa Therapeutics Inc. (Chairman · Since at least Oct 30, 2023); Deciphera Pharmaceuticals LLC (Director · Jun 11, 2024 – Jun 11, 2024 · Past) | Director · Since at least Jan 1, 2024 |
| Jean Liu Other companies: Connect Biopharma Holdings Limited (Board Director · Since at least Mar 16, 2026); Seagen Inc (Chief Legal Officer · Dec 14, 2023 – Dec 14, 2023 · Past) | Director · Since at least Jan 1, 2024 |
| Michael Varney Other companies: Pardes Biosciences Inc (Director · Dec 23, 2021 – Aug 31, 2023 · Past); Foundation Medicine Inc (Director · Apr 7, 2015 – Apr 7, 2015 · Past) | Chair of R&D, SAB Member and Board Director · Since at least Jul 15, 2021 |
| Alexander W. Casdin Other companies: Sientra Inc (Director · Jun 15, 2023 – Jun 15, 2023 · Past) | Director · Since at least Jul 15, 2021 |
| Charles S. Fuchs Other companies: CytomX Therapeutics, Inc. (Director · Since at least Oct 23, 2017) | President, Research and Development · Since at least Aug 10, 2026 |
| Ebun Garner Other companies: Alphatec Holdings, Inc. (General Counsel and SVP · May 15, 2012 – Dec 12, 2016 · Past) | Chief Legal Officer · Since at least Jul 15, 2021 |
| Chandra Lovejoy | Chief Regulatory Affairs Officer · Since at least Nov 5, 2026 |
| David Chacko | Chief Financial Officer and Chief Business Officer · Since at least Nov 5, 2026 |
| Jonathan E. Lim | Chairman, CEO and Co-founder · Since at least Sep 10, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Julie Hambleton | Board Director · Since at least Nov 5, 2026 |
| Lisa Tesvich-Bonora | Chief People Officer · Since at least Nov 5, 2026 |
| Nik Chetwyn | Chief Operating Officer · Since at least Nov 4, 2026 |
| Robert Shoemaker | Chief Scientific Officer · Since at least Nov 12, 2025 |
| Shannon Morris | Chief Medical Officer · Since at least Feb 5, 2024 |
| Valerie Denise Harding Start | Director · Since at least Jun 24, 2025 |
| Val Harding | Board Director · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Erasca, Inc.